Metrics as of 10/14/2026, 12:10 PM (Berlin time), refresh in progress.
Organon & Stock
Organon & Co.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- CEO
- Joseph T. Morrissey Jr.
- Employees
- 10,000
- Market cap
- $3.6 B
- IPO
- 14/05/2021
Organon & Co. is a global pharmaceutical enterprise headquartered in Jersey City, USA, which went public on the NYSE on May 14, 2021. The company is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Organon & stock: price history
1D
-0.2%
1W
-0.4%
1M
+0.7%
6M
+49.2%
YTD
+91.6%
1Y
+43.7%
2Y
-24.1%
5Y
-60.6%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~85% stronger price swings than usual
Organon & stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Organon & Co. is a globally operating pharmaceutical manufacturer serving various therapeutic areas, including women's health, biosimilars, cardiology, respiratory diseases, as well as dermatology and pain management. The company develops and distributes prescription medicines such as contraceptives or preparations for treating high blood pressure and asthma. Distribution takes place through a broad network of medical institutions, pharmacies, wholesalers, as well as government agencies and healthcare organizations.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Organon &
Analyst assessment of Organon &
PRICE TARGET LOW
US$14.00
CONSENSUS
US$14.00
MEDIAN
US$14.00
PRICE TARGET HIGH
US$14.00
0
STRONG BUY
2
BUY
4
HOLD
3
SELL
0
STRONG SELL
9
TOTAL · Hold
As of: 29/04/2026
Organon & stock metrics
P/E
17.39
P/B
3.59
EV/EBITDA
8.4
RETURN ON EQUITY
10.7%
NET MARGIN
6.9%
DEBT/EQUITY
8.5
DIVIDEND YIELD
0.6%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.4%
FLOAT SHARES
261,086,298
AVG. DAILY VOLUME (30D)
2,445,383
Insider transactions (SEC)
Arjona Ferreira Juan Camilo
Arjona Ferreira Juan Camilo
Drinane Juliana Papa
Holzbaur Lynette
Institutional holders
Dividends
Comparable stocks
Frequently asked questions about Organon & stock
What does Organon & do?
Organon & Co. is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in United States.
The CEO is Joseph T. Morrissey Jr., the company employs around 10,000 people.
The IPO was on 14/05/2021; the stock trades on NYSE under the ticker OGN.
What do analysts say about Organon & stock?
9 analysts rate the stock, the consensus is Hold (as of 29/04/2026).
The average price target is US$14.00, ranging from US$14.00 to US$14.00, with a median of US$14.00.
This is an external assessment, not a statement by Market Jury.
When does Organon & report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 85% stronger than usual.
Does Organon & pay a dividend?
Yes. The last dividend was US$0.02 per share, ex-date 14/08/2026, paid on 10/09/2026.
The dividend yield is 0.6% (as of 30/06/2026).
Which stocks are comparable to Organon &?
Comparable stocks include Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck &, Amgen, Gilead Sciences, Pfizer and Bristol-Myers Squibb Company.
How can I get Organon & stock analyzed?
Clicking "Analyze stock" lets five strategies assess Organon & against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.